ArticleCNS neuroscience & therapeutics2026
Urolithin A Exerts Neuroprotective Effects Against Ischemic Stroke by Inhibiting Oxidative Stress and Neuroinflammation.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIschemic stroke (IS), the main stroke type, causes neuronal injury via hypoperfusion and hypoxia, imposes heavy health burdens, and is characterized by neurological deficits driven by oxidative stress and inflammation.
methodsA rat model of IS was established via middle cerebral artery occlusion (MCAO). Sensorimotor and cognitive dysfunctions post-IS were assessed using neurological function scoring, the rotarod test, the adhesive removal test, the foot-fault test, and the Morris water maze (MWM) test. Brain injury was evaluated by TTC staining, immunofluorescence staining, and Western blotting. For mechanistic exploration, RNA transcriptome sequencing analysis, immunofluorescence staining, and ELISA were employed to determine UA's effects on oxidative stress and neuroinflammation following IS.
resultsUA treatment was confirmed to exert neuroprotective effects against ischemic stroke, as it can inhibit neuronal injury and improve sensorimotor and cognitive functions in rats. Mechanistically, UA upregulates the expression of Nrf2/HO-1, thereby enhancing antioxidant capacity characterized by increased levels of antioxidant enzymes (SOD, GSH, GSH-Px) and decreased level of the lipid peroxidation marker MDA. Additionally, UA suppresses neuroinflammation, which is manifested by reduced levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and elevated level of the anti-inflammatory cytokine IL-10. RNA transcriptome sequencing analysis further revealed that these neuroprotective effects of UA may be associated with inhibition of pathological NF-κB activation.
conclusionUrolithin A may exert neuroprotective effects against ischemic stroke by inhibiting oxidative stress and neuroinflammation. Collectively, this study provides theoretical support for the clinical translation of UA as a poststroke neuroprotective agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.